Vaccine Primary vaccination at an interval of 1 month ...

1 Recommended vaccination protocols Parainfluenza (Inactivated). Adenovirus type 2 (MLV). Bordetella (Inactivated). Vaccine Primary vaccination Parainfluenza (MLV). Companion C3.. Puppies from 8 to 12. Parvovirus (MLV). Distemper (MLV). Companion C4.. weeks of age: Inject 2 doses of Vaccine COMPANION. at an interval of 1 month Dogs over 12 weeks of age: For C3 - inject a single dose of Vaccine Vaccine Presentation For C4 - inject 2 doses 1. month apart Companion C3 . 10 doses Companion KC.. Inject 2 doses of Vaccine Companion C4 . 10 doses at an interval of 1 month to dogs 6 weeks of age Companion KC 10 doses or over Companion C5 10 doses Companion C3 + 10 doses An annual booster is recommended Pack Companion KC for all vaccines Recommended vaccination protocols Vaccine Primary vaccination COMPANION Companion F3.

2 Kittens from 8 to 12. Feline panleucopaenia weeks of age: Inject 3 doses of Vaccine Feline Herpes virus C3 AND C4. Feline Calicivirus Feline leukaemia at an interval of 1 month (Recombinant). Cats over 12 weeks of age: Inject 2 doses of Vaccine Modified-live virus (MLV) Vaccine at an interval of 1 month (MLV). (MLV). (MLV). Canine Distemper virus Companion . Inject 2 doses of Vaccine Canine Adenovirus type 2 FeLV at a 2 to 3 week interval Canine Parvovirus Vaccine Presentation to cats 9 weeks of age +/- Canine Parainfluenza virus or over Companion F3 10 doses An annual booster is recommended Early socialisation in puppies Companion FeLV.

3 10 doses for all vaccines 12 week finish Flexibility for 3 dose, 16 week finish protocol if desired Annual boosters REFERENCES. Protective efficacy of each antigen 1. Data on file, study numbers: DA08E002, The Veterinarian, March: 25-27. leukaemia virus Vaccine . Veterinary Record DA08E003, , DA08E004, 6. Richards JR et al. The 2006 American Association 138, 7-11. demonstrated in challenge trials 1. , DA08E005, of Feline Practitioners Feline Vaccine Advisory 10. Hofmann-Lehmann R et al (2007) vaccination 2. Day MJ, Horzinek MC & Schultz RD (2007) Panel Report. against feline leukaemia virus: Outcome and Provides protective immunity against all Guidelines for the vaccination of dogs and cats.

4 7. Horzinek MC & Thiry E (2009) Vaccines and response categories and long-term follow-up. WSAVA vaccination Guidelines Group. vaccination : the principles and the polemics. Vaccine 25, 5531-5539. field strains of canine parvovirus 2. 3. Data on file, study numbers: DM01I001, Journal of Feline Medicine and Surgery 11, 11. Clark N et al (1991) Efficacy and safety field CHPPiI003, CHPPiI002, CHPPiI005. 530-537. trials of a recombinant DNA Vaccine against Safety trials demonstrated no reversion to 4. Data on file: Antibody, challenge and safety 8. Safety trials for APVMA Registration 40759. feline leukaemia virus infection.

5 Journal of the studies (Registration dossier, Part III, pages 22-83) 9. Jarrett O & Ganiere J-P (1996) Comparative American Veterinary Medical Association 199. virulence for any antigen 3. 5. O'Brien C (2007) Feline vaccinations a review. studies of the efficacy of a recombinant feline (10): 1433-43. C3 can be reconstituted with Companion . KC to permit administration of a single C5' vaccination CANINE & FELINE VACCINES. Intervet/Schering-Plough Animal Health 91-105 Harpin Street, Bendigo East VIC 3550. Free Call: 1800 033 461 Free Fax: 1800 817 414. COMPANION KC . COMPANION F3 . COMPANION FeLV . Inactivated Vaccine Modified-live virus (MLV) Vaccine Recombinant Vaccine Bordetella bronchiseptica (Bb) Feline Herpes virus Feline Leukaemia virus Canine Parainfluenza (CPi) virus Feline Calicivirus Feline Panleucopaenia Significant protection Use from 6 weeks of age demonstrated in challenge trials 9-11.

6 MLV vs Inactivated feline vaccines Annual boosters Excellent safety demonstrated MLV under field conditions 11. Provides convenience of administration No adjuvant required to stimulate immunity for fractious dogs Have a rapid onset of immunity 5. Annual boosters More likely to induce a broad range of immune Challenge trial demonstrated significant Can be used as a diluent to responses (humoral and cell-mediated immunity) 5. protection against Bb and CPi 4 reconstitute Companion F3 . Live agent vaccines are better able to overcome MDA in young kittens than are inactivated agent vaccines 6. Can be used as a diluent to reconstitute Companion C3 to permit administration.

7 Inactivated of a single C5' vaccination . Adjuvant required to stimulate immunity With killed' preparations, the chemical or physical treatment used to inactivate the infectivity may damage Technical Services or modify the immunogenicity, which usually results in an immune response of shorter duration, a narrower antigenic spectrum, and weaker cell-mediated and Experienced veterinarians are available to mucosal immune responses 7 provide technical support for Intervet/Schering- Immunity induced by killed agent vaccines is therefore Plough's extensive product range. less likely to provide effective levels of secretory IgA or complete cell-mediated immune protection at mucosal Services and advice include: surfaces in the respiratory and gastrointestinal tracts 6.

8 vaccination protocols Questions re label claims Safety trials demonstrated no disease when Monitoring of post-registration product performance Vaccine virus was administered intranasally 8. Product complaint investigations Annual boosters Can be reconstituted with Companion FeLV . 1800 033 461. Call to speak to one of our Technical Services Veterinarians